HOME >> MEDICINE >> NEWS
Clinical study results using Aldagen's product to isolate cord blood stem cells presented at ASH

Durham, NC -- December 11, 2006 Aldagen, Inc. today announced the presentation of data from a clinical trial using its ALDESORT product to isolate stem cells from cord blood. The trial is being conducted by Joanne Kurtzberg, MD, the Duke University physician who pioneered the use of umbilical cord blood as a treatment for fatal childhood cancers and genetic diseases in 1993. Dr. Kurtzberg presented positive interim results of the study at the 48th Annual Meeting of the American Society of Hematology in Orlando, Florida.

About the Study
ALDESORT enriches a unique population of stem and progenitor cells from cord blood that contribute to neutrophil and platelet engraftment and to immune reconstitution following transplantation. The primary goal of the clinical study is to determine if transplanting these enriched cells is safe. The study will also indicate if transplanting these cell populations could result in accelerated engraftment and lead to more favorable clinical outcomes compared to a historical control group from the Cord Blood Transplantation Trial (COBLT) study, a multicenter Phase II study sponsored by the National Heart, Lung and Blood Institute. At the time of the interim analysis, eleven pediatric patients with cancer or genetic diseases were transplanted with unrelated donor umbilical cord blood and a supplement of cord cells isolated using ALDESORT. Overall survival at 180 days was 90.9%, compared to an overall survival at 180 days of 57% in COBLT study. The cumulative incidence of neutrophil engraftment by day 42 was 90.9% (p=0.001) and platelet engraftment by day 100 was 79.5% (p=0.003).

The findings of this study once again show the promise of transplanting stem cells from umbilical cord blood to treat children with resistant cancers and genetic diseases, said Dr. Kurtzberg. The infusion of cells enriched with ALDESORT has had no adverse effects and appears to improve the speed and efficacy of cord bloo
'"/>

Contact: Michelle Linn
linnmich@comcast.net
508-419-1555
Linnden Communications
11-Dec-2006


Page: 1 2

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
6. Clinical guidelines for blood conservation during cardiac procedures developed
7. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
8. Clinical trial coordinators need more financial conflict-of-interest training
9. Clinical studies evaluate potential treatments for mouth ulcers
10. NIH names Clinical Trial Units for the Microbicide Trials Network
11. Clinical Trials Units selected for newly restructured HIV/AIDS research networks

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... The National Business Research ... National Registry of Emergency Medical Technicians and welcomes this organization to the ... Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. “This award ...
(Date:4/26/2017)... ... April 26, 2017 , ... Miami native and local periodontist Dr. John ... have never imagined back in 1991 that this journey would have taken me into ... last 25 years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more ... CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology is a more ... with fewer resources. It highlights the business’ principles, research and collaboration efforts in ...
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, ... the first in a new class of photodynamic cosmetics (PDC). , Allumera® is ... visibly reduce outward signs of aging, and minimize the appearance of pores – ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... VANCOUVER , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) ... the Bloom Burton & Co. Healthcare Investor Conference 2017 at the ... Edward Wright , Chief Executive Officer of the Company is ... Company,s CFO, Richard Bear and the Chairman of the ... ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
Breaking Medicine Technology:
Cached News: